Literature DB >> 35669481

Editorial: Clinical Cases in Cardiovascular Medicine: 2021.

Maurizio Acampa1, Leonardo Roever2.   

Abstract

Entities:  

Keywords:  Wolff-Parkinson-White syndrome; eosinophilic granulomatosis; extracorporeal shockwave myocardial revascularization; multisystem inflammatory syndrome; myocardial bridging; myocardial infarction; pheocromocytoma; systemic inflammation

Year:  2022        PMID: 35669481      PMCID: PMC9164012          DOI: 10.3389/fcvm.2022.930230

Source DB:  PubMed          Journal:  Front Cardiovasc Med        ISSN: 2297-055X


× No keyword cloud information.
In the present Frontiers Research Topic, an international selection of high-quality case reports contributed to advance our understanding of personalized approaches to cardiovascular diagnosis and treatment, beginning with the patient physician communication, to bedside clinical assessment, advanced diagnostic and imaging technologies. Indeed, these case reports provided insight into the differential diagnosis, decision making, and clinical management of unusual cases, also representing a valuable educational tool. Several contributions (Li and Liu; Wu et al.; Ye et al.) focused on rare symptoms that can be occur in specific cardiac diseases, suggesting the presence of multiple and complex pathogenic mechanisms (1, 2). In this view, Ye et al. presented a case of acute myocardial infarction as a rare complication of acute chlorpyrifos poisoning. The complex relationships between poisoning and myocardial infarction are not only represented by the great variety of symptoms, but also by the conflicts of treatments for both conditions. Indeed, atropinization contributes to the control of muscarinic symptoms of chlorpyrifos poisoning, but can also increase the heart rate and myocardial oxygen consumption, which can worse myocardial ischemia. Wu et al. showed that some pathological conditions can be diagnosed at the onset of rare symptoms, apparently unrelated with the disease as in the case of a hypertensive 59-older patient with covert pheochromocytoma who had a sudden hypotension and shock. These symptoms are rare and apparently inconsistent with pheocromocytoma, but a possible pathogenic explanation can be related to tumor necrosis that leads to a sudden decrease in continuous catecholamine secretion, with subsequent hypotension. Furthermore, Li and Liu described another atypical case characterized by a usually benign cardiac congenital anatomical variation, the myocardial bridging (MB) of the coronary artery. However, in the case of a 41-year-old man, the association between MB and hypothyroidism contributed to the occurrence of myocardial infarction. In fact, MB initiated the development of coronary atherosclerotic lesions, but hypothyroidism further contributed to the occurrence of myocardial infarction by multiple mechanisms including endothelial dysfunction, increased platelet activation, hypercholesterolemia, increased levels of low-density lipoprotein cholesterol, and hypertriglyceridemia. Another study by Akbar et al. focused on the efficacy of specific therapies, such as extracorporeal shockwave myocardial revascularization. Akbar et al. presented a case series of four patients with coronary artery bypass grafting-stable angina pectoris who refused surgery and who underwent extracorporeal shockwave myocardial revascularization obtaining an improvement of the ischemic response, functional capacity, and physical component of quality of life. Systemic inflammation is another pathogenic factor that can interact at multiple levels on the cardiovascular system and many case reports in the present Research Topic pointed out its relevant role. Immuno-inflammatory mechanisms may play a relevant pathogenic role in some cardiac diseases, contributing to development of coronary artery disease (3) and cardiac arrhythmias, modulating both atrial (4, 5) and ventricular substrates (6). The role of inflammatory cytokines has recently become more clear with COVID-19, a systemic inflammatory disease, that can cause myocardial injury (7, 8), with an unexpectedly high prevalence of arrhythmic events (9). In this respect, Bemtgen et al. described a case of an 18-year-old male patient affected by a multisystem inflammatory syndrome, a novel hyperinflammatory syndrome associated with SARS-CoV-2 infection, where a myocardial biopsy revealed small vessel-associated immune cell infiltrates, without myocardial necrosis, with fast and favorable response to immunomodulatory therapy. Inflammation can also play an important role in other inflammatory diseases: Cui et al. described an interesting case of eosinophilic granulomatosis with polyangiitis that was manifested as myocardial infarction with non-obstructed coronary arteries. Also in this case, the immunosuppressive therapy led to regression of symptoms with significant clinical resolution. Alania-Torres et al. described a rare case of patient affected by arrhythmogenic left ventricular cardiomyopathy who developed a myocarditis induced by coronavirus disease 2019 (COVID-19) mRNA vaccine. This case report is particularly interesting from a diagnostic and pathogenic point of view, because both conditions myocarditis and a hot phase of the arrhythmogenic left ventricular cardiomyopathy can have similar ECG, echocardiographic and MRI findings and, moreover, both might be pathophysiologically related. Yang et al. suggested the further complexity of the relationships between immune modulation and cardiac disease presenting a case of a 33-year-old man with a history of metastatic thymoma treated with sintilimab, who developed grade 3 immune checkpoint inhibitor (ICI)-related myocarditis, complicated with myositis/myasthenia gravis. Wang et al. described a case of a patient with pneumonia and myocarditis, characterized by the coexistence of Wolff-Parkinson-White (WPW) syndrome and Brugada electrocardiogram (ECG) patterns. Even if this association has already been reported in previous papers, the peculiarity of this case is due to the particular dynamic changes of QRS complex, relating to fever, suggesting the possible modulating role of inflammation on cardiac electrical activity. In conclusion, the high-quality contributions presented in this Research Topic significantly enriched our knowledge about the field of cardiovascular diseases, shedding light on rare symptoms, complex physiologic and pathogenic mechanisms, that can have relevant implications also for the choice of appropriate treatments in these patients. These studies also provide important suggestions for further investigation in this area.

Author Contributions

MA and LR contributed to the conception, design, and drafting of the work. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  9 in total

Review 1.  Systems-based approaches to cardiovascular disease.

Authors:  W Robb MacLellan; Yibin Wang; Aldons J Lusis
Journal:  Nat Rev Cardiol       Date:  2012-01-10       Impact factor: 32.419

2.  The Impact of COVID-19 on the Cardiovascular System.

Authors:  Roque Aras Júnior; André Durães; Leonardo Roever; Cristiano Macedo; Marcela Gordilho Aras; Luca Nascimento; Alex Cleber Improta-Caria; Ricardo Augusto Leoni De Sousa; Mansueto Gomes-Neto
Journal:  Rev Assoc Med Bras (1992)       Date:  2021-07-09       Impact factor: 1.209

3.  Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin-6-Mediated Changes in Connexin Expression.

Authors:  Pietro Enea Lazzerini; Franco Laghi-Pasini; Maurizio Acampa; Ujala Srivastava; Iacopo Bertolozzi; Beatrice Giabbani; Francesco Finizola; Francesca Vanni; Aleksander Dokollari; Mariarita Natale; Gabriele Cevenini; Enrico Selvi; Nicola Migliacci; Massimo Maccherini; Mohamed Boutjdir; Pier Leopoldo Capecchi
Journal:  J Am Heart Assoc       Date:  2019-08-19       Impact factor: 5.501

4.  Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokine-Mediated Inhibition of Connexin43 Expression.

Authors:  Pietro Enea Lazzerini; Maurizio Acampa; Michael Cupelli; Alessandra Gamberucci; Ujala Srivastava; Claudio Nanni; Iacopo Bertolozzi; Francesca Vanni; Alessandro Frosali; Anna Cantore; Alessandra Cartocci; Antonio D'Errico; Viola Salvini; Riccardo Accioli; Decoroso Verrengia; Fabio Salvadori; Aleksander Dokollari; Massimo Maccherini; Nabil El-Sherif; Franco Laghi-Pasini; Pier Leopoldo Capecchi; Mohamed Boutjdir
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

5.  Multi-omics approaches for revealing the complexity of cardiovascular disease.

Authors:  Stephen Doran; Muhammad Arif; Simon Lam; Abdulahad Bayraktar; Hasan Turkez; Mathias Uhlen; Jan Boren; Adil Mardinoglu
Journal:  Brief Bioinform       Date:  2021-03-17       Impact factor: 11.622

Review 6.  COVID-19, Acute Myocardial Injury, and Infarction.

Authors:  Armando Del Prete; Francesca Conway; Domenico G Della Rocca; Giuseppe Biondi-Zoccai; Francesco De Felice; Carmine Musto; Marco Picichè; Eugenio Martuscelli; Andrea Natale; Francesco Versaci
Journal:  Card Electrophysiol Clin       Date:  2021-10-30

7.  Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19.

Authors:  Franco Laghi-Pasini; Mohamed Boutjdir; Pier Leopoldo Capecchi; Pietro Enea Lazzerini
Journal:  Nat Rev Immunol       Date:  2022-05       Impact factor: 53.106

Review 8.  Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.

Authors:  Nicholas J Montarello; Mau T Nguyen; Dennis T L Wong; Stephen J Nicholls; Peter J Psaltis
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-10       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.